LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today, and Tomorrow?
Nov
16
2024
Marriott Marquis: Grand Ballroom 346
7:30 PM - 9:30 PM
Description
As the treatment landscape for hepatocellular carcinoma (HCC) continues to evolve, multidisciplinary, coordinated therapeutic intervention remains the cornerstone of care for these patients. Expert insights into treatment selection and collaborative decision-making are critical to informing and optimizing patient outcomes in resectable and unresectable disease.This hybrid Liver Cancer Tumor Board® symposium will bring together renowned experts in the management of HCC. In this educational program, these experts will share clinical insights and advances in the management of HCC with novel neoadjuvant, adjuvant, and perioperative immunotherapy-based therapeutic strategies.
Supported by: AstraZeneca, Inc.
For more information and to register, visit: https://www.gotoper.com/courses/liver-cancer-meeting
Objectives
- Assess the efficacy and safety of current and emerging adjuvant and neoadjuvant treatment strategies for early-stage resectable hepatocellular carcinoma (HCC) and appropriate patient selection
- Analyze the efficacy and safety of current and emerging therapies and combinations for management of patients with intermediate stage and advanced/metastatic HCC
- Develop personalized care plans for patients with early-, intermediate-stage as well as advanced/metastatic HCC by integrating clinical trial evidence, expert guidelines, tumor characteristics, patient co-morbidities, and goals of therapy
- Devise proactive plans for monitoring and mitigating treatment-related adverse events associated with current and emerging therapies for patients with HCC